Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ALDH3A1 | P30838 | 3/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | DDO | Q99489 | 1/20 | 0.33 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.33 |
| ▸ | CCKAR | P32238 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.32 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749189 | 0.88 | PTGDR2 (0.37) | PTGDR2ALDH3A1CCKARALDH1A1LMNA | |
| SCHEMBL5002087 | 0.85 | SRC (0.39) | SRCPTGDR2BRD4ALDH3A1DCTPP1 | |
| SCHEMBL21470469 | 0.85 | SRC (0.39) | SRCPTGDR2BRD4ALDH3A1CCKAR | |
| SCHEMBL29772734 | 0.85 | SRC (0.39) | SRCPTGDR2BRD4ALDH3A1CCKAR | |
| SCHEMBL16977994 | 0.85 | PTGDR2 (0.40) | SRCSLC40A1PTGDR2BRD4ALDH3A1 | |
| SCHEMBL16982119 | 0.84 | PTGDR2 (0.39) | SRCSLC40A1PTGDR2BRD4ALDH1A1 | |
| SCHEMBL5661951 | 0.78 | ENPP3 (0.44) | SRCSLC40A1PTGDR2ALDH3A1ALDH1A1 | |
| SCHEMBL5004901 | 0.78 | SRC (0.41) | SRCPTGDR2ALDH3A1DCTPP1ALDH1A1 | |
| SCHEMBL30751165 | 0.78 | ENPP3 (0.44) | SRCSLC40A1PTGDR2ALDH3A1ALDH1A1 | |
| SCHEMBL16041786 | 0.75 | CYP2C19 (0.48) | SLC40A1ALDH1A1LMNAHTTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796708-B2 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9073922-B2 | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | SRC 616/4885SLC40A1 4703/4885PTGDR2 590/4885 |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | SRC 479/4885SLC40A1 4570/4885PTGDR2 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.